HealthLawProf Blog

Editor: Katharine Van Tassel
Case Western Reserve University School of Law

Saturday, August 6, 2011

Stacey B. Lee: "Generic Manufacturers' Labeling Catch-22"

Stacey B. Lee, Assistant Professor at Johns Hopkins University Carey Business School, posted, "Generic Manufacturers' Labeling Catch-22" on SSRN:

Stacey In Wyeth v. Levine, the Supreme Court eliminated brand-name manufacturers’ ability to use the preemption defense against state law failure to warn claims involving allegedly misbranded pharmaceutical drugs. Since that time, a heated debate has ensued among federal courts and legal scholars regarding that holding’s effect on generic manufacturers. Lost amid these judicial opinions and scholarly articles, however, is a more fundamental inquiry. Regardless of whether preemption is a viable defense, what type of legal and regulatory framework is needed to ensure generic manufacturers possess the necessary tools to fulfill their responsibility of providing consumers and the medical community with current and accurate labeling instructions for their products? This Article proposes such a framework.

| Permalink

TrackBack URL for this entry:

Listed below are links to weblogs that reference Stacey B. Lee: "Generic Manufacturers' Labeling Catch-22":


Post a comment